Novavax Inc vs Advanced Drainage Systems Inc — how do they compare? Novavax Inc trades at $11.1 (market cap $1.82B), while Advanced Drainage Systems Inc trades at $127.14 (market cap $9.52B). The key difference: Advanced Drainage Systems Inc is far larger — about 5.2× Novavax Inc's market cap, and Advanced Drainage Systems Inc pays a 0.63% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Advanced Drainage Systems Inc for 43 Days on average.
| NVAX | WMS | |
|---|---|---|
Market Cap | $1.82B | $9.52B |
Volume | 6,198,505 | 907,564 |
Sector | Health | Basic Materials |
52-Week High | $12.56 | $175.38 |
52-Week Low | $6.22 | $125.33 |
Typical Hold Time | 59 Days | 43 Days |
Enterprise Value | $1.39B | $11.12B |
Dividend Yield | — | 0.63% |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
Advanced Drainage Systems (WMS) trades at $126.08, down 3.07% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.49 exceeding expectations. Revenue for 2025 was $2.90 billion, with a net income margin of 15.5%. The company maintains strong profitability metrics, including a 24.9% ROE, and recently announced a quarterly dividend. Analyst consensus is mixed with a $188.70 price target, while institutional activity shows both new acquisitions and reductions in holdings.
WMS presents a balanced outlook with solid fundamentals and recent earnings beats offset by near-term technical weakness. Investment opportunities include sustained revenue growth and margin expansion from operational efficiencies. Key risks involve competitive pressures in the construction sector and potential volatility from macroeconomic factors. The stock's current valuation at a P/E of 21.48 offers a reasonable entry point relative to growth prospects, but investors should monitor cash flow trends given the projected net cash outflow in 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →